{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:11:23Z","timestamp":1794640283862,"version":"4.9.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019298","name":"Greenwich Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019298","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eplepsyres.2023.107280","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:43:48Z","timestamp":1702532628000},"page":"107280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey"],"prefix":"10.1016","volume":"200","author":[{"given":"Anne T.","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Dixon-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Meskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry R.","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Minh D.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Scott","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2023.107280_bib1","unstructured":"21st Century Cures Act. https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act; 2023 [Accessed 31 July 2023]."},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107280_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11136-019-02409-0","article-title":"Development and validation of the University of Washington caregiver stress and benefit scales for caregivers of children with or without serious health conditions","volume":"29","author":"Amtmann","year":"2020","journal-title":"Qual. Life Res"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107280_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107280_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0883073809348355","article-title":"Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms","volume":"25","author":"Autry","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107280_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12319","article-title":"Seizure burden in severe early-life epilepsy: perspectives from parents","volume":"4","author":"Berg","year":"2019","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107280_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/epi.16750","article-title":"SCN2A-developmental and epileptic encephalopathies: challenges to trial-readiness for non-seizure outcomes","volume":"62","author":"Berg","year":"2021","journal-title":"Epilepsia"},{"issue":"152","key":"10.1016\/j.eplepsyres.2023.107280_bib9","doi-asserted-by":"crossref","first-page":"152ra127","DOI":"10.1126\/scitranslmed.3004214","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial","volume":"4","author":"Berry-Kravis","year":"2012","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107280_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107280_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107280_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yebeh.2006.10.010","article-title":"The development and validation of the epilepsy and learning disabilities quality of life (ELDQOL) scale","volume":"10","author":"Buck","year":"2007","journal-title":"Epilepsy Behav."},{"issue":"Suppl 5","key":"10.1016\/j.eplepsyres.2023.107280_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yebeh.2018.01.003","article-title":"Assessing the impact of caring for a child with Dravet syndrome: results of a caregiver survey","volume":"80","author":"Campbell","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"8","key":"10.1016\/j.eplepsyres.2023.107280_bib15","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/epi.13441","article-title":"Correlates of health-related quality of life in children with drug resistant epilepsy","volume":"57","author":"Conway","year":"2016","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107280_bib16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/epi.13697","article-title":"Validating the shortened quality of life in childhood epilepsy questionnaire (QOLCE-55) in a sample of children with drug-resistant epilepsy","volume":"58","author":"Conway","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front Neurol."},{"issue":"21","key":"10.1016\/j.eplepsyres.2023.107280_bib18","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"20","key":"10.1016\/j.eplepsyres.2023.107280_bib19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizure frequency in patients with Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2023.107280_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2023.107280_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11073","article-title":"Anti-seizure medications and quality of life in person with epilepsy","volume":"8","author":"Dwivedi","year":"2022","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107280_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib23","unstructured":"EPIDIOLEX\u00ae (cannabidiol) [prescribing information]. 2023 [Accessed 9 February 2023]."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib24","unstructured":"FDA. (2023). FDA patient-focused drug development guidance series for enhancing the incorporation of the patient's voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical."},{"issue":"8","key":"10.1016\/j.eplepsyres.2023.107280_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2009.06.005","article-title":"Impact of Lennox-Gastaut syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review","volume":"18","author":"Gallop","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2019.03.035","article-title":"Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy","volume":"95","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/JMDH.S69300","article-title":"Lennox-Gastaut syndrome: impact on the caregivers and families of patients.","volume":"7","author":"Gibson","year":"2014","journal-title":"J. Multidiscip. Health"},{"issue":"3","key":"10.1016\/j.eplepsyres.2023.107280_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/epi.14008","article-title":"Development and assessment of the quality of life in childhood epilepsy questionnaire (QOLCE-16)","volume":"59","author":"Goodwin","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib29","unstructured":"Hagopian, S., Whitmire, A., Little, K., Thomas, D., Minnick, J. Is this the CBD? Qualitative results of positive non-seizure related outcomes in four expanded access programs, https:\/\/www.aesnet.org\/abstractslisting\/is-this-the-cbd-qualitative-results-of-positive-non-seizure-related-outcomes-in-four-expanded-access-programs; 2019 [Accessed 18 June 2022]."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib30","first-page":"CD003277","article-title":"Treatment of Lennox-Gastaut syndrome","volume":"2","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.eplepsyres.2023.107280_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s11689-018-9229-x","article-title":"Few individuals with Lennox-Gastaut syndrome have autism spectrum disorder: a comparison with Dravet syndrome","volume":"10","author":"He","year":"2018","journal-title":"J. Neurodev. Disord."},{"issue":"S4","key":"10.1016\/j.eplepsyres.2023.107280_bib32","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1017\/S0317167100034934","article-title":"Consequences of epilepsy: why do we treat seizures?","volume":"25","author":"Jones","year":"1998","journal-title":"Can. J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.eplepsyres.2023.107280_bib33","first-page":"308","article-title":"Quality of life of children and adolescents from Sao Paulo: reliability and validity of the Brazilian version of the Pediatric Quality of Life Inventory version 4.0 Generic Core Scales","volume":"84","author":"Klatchoian","year":"2008","journal-title":"J. Pedia (Rio J. )"},{"issue":"10","key":"10.1016\/j.eplepsyres.2023.107280_bib34","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s42399-021-00989-y","article-title":"Comorbidities in Dravet syndrome and Lennox\u2013Gastaut syndrome","volume":"3","author":"Marchese","year":"2021","journal-title":"SN Compr. Clin. Med"},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107280_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2023.107280_bib36","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox\u2013Gastaut syndrome: Results of a long-term open-label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib37","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory; 2023 [Accessed 3 July 2023]."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib38","unstructured":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome; 2022 [Accessed 3 July 2023]."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107316","article-title":"Objectively measured sleep-wake patterns in patients with drug-resistant epilepsy - Interaction with quality of life and antiepileptic treatment","volume":"112","author":"Pavlova","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2023.107280_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jpepsy\/jsi071","article-title":"Psychopathology in children with epilepsy: a meta-analysis","volume":"30","author":"Rodenburg","year":"2005","journal-title":"J. Pedia Psychol."},{"issue":"8","key":"10.1016\/j.eplepsyres.2023.107280_bib41","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2023.107280_bib42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/ebeh.2000.0049","article-title":"Epilepsy: quality of life and cost of care","volume":"1","author":"Schachter","year":"2000","journal-title":"Epilepsy Behav."},{"issue":"10","key":"10.1016\/j.eplepsyres.2023.107280_bib43","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2023.107280_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1528-1167.2011.03012.x","article-title":"Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief","volume":"52","author":"Skluzacek","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2023.107280_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"issue":"10125","key":"10.1016\/j.eplepsyres.2023.107280_bib46","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eplepsyres.2023.107280_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1528-1157.1997.tb00065.x","article-title":"Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children","volume":"38","author":"Trevathan","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2023.107280_bib48","unstructured":"US Food and Drug Administration. Rare Diseases: Common Issues in Drug Development Guidance for Industry, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry; 2019 [Accessed 12 July 2022]."},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107280_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4414\/sanp.2013.00174","article-title":"Dravet syndrome: an update","volume":"164","author":"van Dam","year":"2013","journal-title":"Schweiz Arch. Neurol. Psychiatr."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"8","key":"10.1016\/j.eplepsyres.2023.107280_bib51","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0883073819836534","article-title":"Evaluation of the effects of clobazam on seizure control and quality of life in children With Lennox-Gastaut syndrome: a pilot study","volume":"34","author":"Weinstock","year":"2019","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2023.107280_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pedia Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2023.107280_bib53","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","article-title":"Incidence of Dravet syndrome in a US population","volume":"136","author":"Wu","year":"2015","journal-title":"Pediatrics"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112300205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112300205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T22:16:12Z","timestamp":1736201772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012112300205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":53,"alternative-id":["S092012112300205X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107280","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107280"}}